Clinical Trial Update: A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

View source ↗

Summary

A prospective cohort study evaluating Zorifertinib as first-line therapy for EGFR-mutant advanced non-small cell lung cancer with brain/CNS metastases; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Zorifertinib (Zorifertinib)

Snippet

Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. | Conditions: EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases | Status: RECRUITING